NPI: 1821103516 · PONTOTOC, MS 38863 · Critical Access Hospital · NPI assigned 08/20/2006
Authorized official TOPPIN, BRUCE controls 20+ related entities in our dataset. Read more
| Authorized Official | TOPPIN, BRUCE (CORPORATE SECRETARY) |
| Parent Organization | PONTOTOC HEALTH SERVICES, INC. |
| NPI Enumeration Date | 08/20/2006 |
Other providers sharing the same authorized official: TOPPIN, BRUCE
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 24,103 | $1.49M |
| 2019 | 26,864 | $1.90M |
| 2020 | 24,469 | $1.45M |
| 2021 | 24,894 | $1.54M |
| 2022 | 29,280 | $1.70M |
| 2023 | 39,684 | $1.99M |
| 2024 | 31,237 | $1.48M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 14,794 | 11,782 | $3.15M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 12,868 | 9,705 | $1.70M |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 11,364 | 1,557 | $1.50M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3,165 | 2,678 | $928K |
| 87428 | 7,906 | 6,786 | $401K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3,153 | 2,774 | $377K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 5,588 | 1,419 | $278K |
| 70450 | Computed tomography, head or brain; without contrast material | 2,428 | 2,168 | $276K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 5,752 | 4,798 | $264K |
| 71045 | Radiologic examination, chest; single view | 5,167 | 4,451 | $257K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5,464 | 1,091 | $239K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 753 | 675 | $237K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3,156 | 2,580 | $195K |
| 71046 | Radiologic examination, chest; 2 views | 2,811 | 2,492 | $138K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1,161 | 798 | $133K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4,065 | 3,455 | $126K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1,023 | 900 | $123K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 446 | 397 | $119K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2,661 | 2,249 | $109K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2,098 | 1,731 | $102K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 14,255 | 11,558 | $81K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 6,455 | 5,588 | $81K |
| 80053 | Comprehensive metabolic panel | 9,775 | 8,278 | $74K |
| 72125 | Computed tomography, cervical spine; without contrast material | 358 | 322 | $59K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3,462 | 1,832 | $54K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 879 | 757 | $49K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1,724 | 1,169 | $46K |
| 80048 | Basic metabolic panel (calcium, ionized) | 4,896 | 3,965 | $31K |
| 84443 | Thyroid stimulating hormone (TSH) | 2,262 | 2,053 | $27K |
| 80061 | Lipid panel | 2,502 | 2,284 | $27K |
| 83880 | 1,194 | 1,048 | $26K | |
| 84484 | 3,339 | 2,643 | $26K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 322 | 270 | $25K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1,529 | 1,335 | $23K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2,535 | 2,337 | $21K |
| 36415 | Collection of venous blood by venipuncture | 6,840 | 5,067 | $14K |
| 87081 | 2,484 | 2,226 | $14K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 104 | 91 | $14K |
| 87807 | 1,267 | 1,098 | $13K | |
| 83690 | 2,317 | 2,043 | $11K | |
| 81001 | 4,193 | 3,657 | $11K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 537 | 487 | $10K |
| 87040 | 1,513 | 771 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1,684 | 1,481 | $9K |
| 81025 | 1,153 | 1,026 | $8K | |
| 73630 | 162 | 136 | $8K | |
| 80076 | 1,083 | 1,003 | $7K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1,467 | 1,270 | $6K |
| 82728 | 677 | 590 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 2,651 | 2,211 | $5K |
| 73030 | 89 | 80 | $5K | |
| 81003 | 2,403 | 2,143 | $5K | |
| Q3014 | Telehealth originating site facility fee | 352 | 311 | $5K |
| 87077 | 775 | 662 | $4K | |
| 87186 | 748 | 646 | $4K | |
| 82607 | 446 | 401 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1,959 | 1,669 | $4K |
| 83605 | 669 | 535 | $4K | |
| 83735 | 940 | 762 | $4K | |
| 73562 | 75 | 70 | $3K | |
| 83550 | 582 | 513 | $3K | |
| 84703 | 587 | 502 | $3K | |
| 85027 | 542 | 453 | $3K | |
| 83540 | 701 | 623 | $3K | |
| 74018 | 67 | 61 | $3K | |
| 90832 | Psychotherapy, 30 minutes with patient | 45 | 30 | $3K |
| 96376 | 220 | 166 | $3K | |
| 72100 | 46 | 39 | $3K | |
| 97161 | 15 | 14 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 34 | 33 | $2K |
| 73610 | 46 | 38 | $2K | |
| 87400 | 82 | 73 | $2K | |
| 80305 | 129 | 123 | $1K | |
| 92526 | 33 | 12 | $1K | |
| 85610 | 587 | 298 | $1K | |
| 86140 | 329 | 279 | $1K | |
| A9270 | Non-covered item or service | 1,518 | 1,160 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 46 | 38 | $1K |
| 82550 | 187 | 150 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 796 | 656 | $1K |
| 82553 | 102 | 92 | $987.65 | |
| 97165 | 29 | 28 | $962.92 | |
| 85379 | 91 | 84 | $774.08 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 2,190 | 1,911 | $702.81 |
| 82962 | 258 | 176 | $582.39 | |
| 82570 | 69 | 61 | $534.94 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 14 | 12 | $519.01 |
| 82044 | 35 | 30 | $381.47 | |
| 86308 | 57 | 42 | $359.61 | |
| 73502 | 16 | 12 | $332.70 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 12 | 12 | $316.76 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 12 | 12 | $316.76 |
| 82948 | 79 | 45 | $295.10 | |
| 99305 | 12 | 12 | $271.04 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 357 | 315 | $262.36 |
| 86738 | 21 | 20 | $254.41 | |
| 90715 | 46 | 38 | $237.34 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 1,064 | 877 | $209.17 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 304 | 267 | $203.61 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 77 | 67 | $176.08 |
| 99307 | 23 | 13 | $157.89 | |
| J7050 | Infusion, normal saline solution, 250 cc | 109 | 83 | $151.16 |
| 82150 | 32 | 30 | $129.95 | |
| 84145 | 377 | 335 | $126.11 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 126 | 82 | $103.66 |
| 83615 | 19 | 14 | $76.21 | |
| 82043 | 17 | 16 | $59.42 | |
| 85652 | 27 | 24 | $43.84 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 35 | 29 | $43.40 |
| J2060 | Injection, lorazepam, 2 mg | 22 | 12 | $7.75 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 37 | 27 | $4.48 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 92 | 75 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 66 | 63 | $0.00 |
| 36416 | 198 | 167 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 16 | 12 | $0.00 |